Clinical Trial

Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated September 16, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy Chinese subjects at single dose administration of Allisartan Isoproxil Tablets (240 mg ,480 mg or 720 mg）or placebo. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of Allisartan Isoproxil Tablets.
Trial Details
NCT Number NCT07174830
Lead Sponsor Shenzhen Salubris Pharmaceuticals Co., Ltd.
Conditions Healthy Participants
Enrollment 54 participants
Start Date 2025-09-06
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-02-16 (estimated)
Updated on ClinicalTrials.gov 2025-09-16